Literature DB >> 19307028

Drug development and the cellular quality control system.

P Michael Conn1, Jo Ann Janovick.   

Abstract

Proteins serve in cellular roles that necessitate structural precision, a requirement overseen by the cellular quality control system (QCS). By rejecting misfolded proteins, the QCS protects against aberrant activity. Misfolding and subsequent retention by the QCS results in proteins that might maintain function but become misrouted and cause disease. Correcting the misrouting of misfolded mutant proteins often restores activity and addresses the underlying disease. Because of its small size, the gonadotropin-releasing hormone receptor has been an excellent model for G-protein-coupled receptor trafficking and has recently enabled elucidation of both the requirements to pass the QCS and the biochemical mechanism of rescue by pharmacological chaperones; this information will now enable rational design of these therapeutic agents. Here, we summarize what is known about the relation between receptor structure and interactions with the QCS with a view toward therapeutic development based on the rescue of misfolded and, consequently, misrouted mutants with drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19307028     DOI: 10.1016/j.tips.2009.02.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  26 in total

Review 1.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

2.  Rescue of misrouted GnRHR mutants reveals its constitutive activity.

Authors:  Jo Ann Janovick; Irina D Pogozheva; Henry I Mosberg; Anda Cornea; P Michael Conn
Journal:  Mol Endocrinol       Date:  2012-05-17

3.  Dominant protein interactions that influence the pathogenesis of conformational diseases.

Authors:  Jordan Wright; Xiaofan Wang; Leena Haataja; Aaron P Kellogg; Jaemin Lee; Ming Liu; Peter Arvan
Journal:  J Clin Invest       Date:  2013-06-03       Impact factor: 14.808

4.  Functional rescue of Kallmann syndrome-associated prokineticin receptor 2 (PKR2) mutants deficient in trafficking.

Authors:  Dan-Na Chen; Yan-Tao Ma; Huadie Liu; Qun-Yong Zhou; Jia-Da Li
Journal:  J Biol Chem       Date:  2014-04-21       Impact factor: 5.157

Review 5.  Trafficking and signalling of gonadotrophin-releasing hormone receptors: an automated imaging approach.

Authors:  A R Finch; K R Sedgley; S P Armstrong; C J Caunt; C A McArdle
Journal:  Br J Pharmacol       Date:  2009-11-03       Impact factor: 8.739

Review 6.  Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.

Authors:  Alfredo Ulloa-Aguirre; Teresa Zariñán; James A Dias; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2013-06-24       Impact factor: 4.102

Review 7.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

8.  Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy.

Authors:  Jo Ann Janovick; M David Stewart; Darla Jacob; L D Martin; Jian Min Deng; C Allison Stewart; Ying Wang; Anda Cornea; Lakshmi Chavali; Suhujey Lopez; Shoukhrat Mitalipov; Eunju Kang; Hyo-Sang Lee; Pulak R Manna; Douglas M Stocco; Richard R Behringer; P Michael Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

Review 9.  Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.

Authors:  P Michael Conn; Alfredo Ulloa-Aguirre
Journal:  Trends Endocrinol Metab       Date:  2009-12-11       Impact factor: 12.015

10.  Molecular basis of the dominant negative effect of a glycine transporter 2 mutation associated with hyperekplexia.

Authors:  Esther Arribas-González; Jaime de Juan-Sanz; Carmen Aragón; Beatriz López-Corcuera
Journal:  J Biol Chem       Date:  2014-12-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.